# Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer

> **NCT02559024** · PHASE1 · TERMINATED · sponsor: **Providence Health & Services** · enrollment: 4 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** MEDI6469

## Key facts

- **NCT ID:** NCT02559024
- **Lead sponsor:** Providence Health & Services
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03-14
- **Primary completion:** 2018-10
- **Final completion:** 2018-10
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Drug expired and access to additional supply ended. PI left the institution shortly afterwards and the study will not be re-activated. Only 4 patients were enrolled.
- **Last updated:** 2022-02-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02559024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02559024, "Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02559024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*